Literature DB >> 21509250

The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?

Elias A Said1.   

Abstract

Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.

Entities:  

Keywords:  Hepatitis C virus; Infection; Interferon; Liver; MicroRNAs; Therapy

Year:  2010        PMID： 21509250      PMCID： PMC3074728     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN： 2075-051X


  25 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

Authors: 
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

Review 3.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 4.  Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.

Authors:  Stefan Zeuzem; Fred Poordad
Journal:  Curr Med Res Opin       Date:  2010-07       Impact factor: 2.580

5.  CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes.

Authors:  Li Ye; Xu Wang; Shihong Wang; Yanjian Wang; Li Song; Wei Hou; Lin Zhou; He Li; Wenzhe Ho
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  Activation of hepatitis C virus translation by a liver-specific microRNA.

Authors:  Michael Niepmann
Journal:  Cell Cycle       Date:  2009-05-04       Impact factor: 4.534

7.  Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus.

Authors:  Robert E Lanford; Bernadette Guerra; Catherine B Bigger; Helen Lee; Deborah Chavez; Kathleen M Brasky
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

8.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy.

Authors:  Magdalena Sarasin-Filipowicz; Jacek Krol; Ilona Markiewicz; Markus H Heim; Witold Filipowicz
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

9.  Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey.

Authors:  F McOmish; P L Yap; B C Dow; E A Follett; C Seed; A J Keller; T J Cobain; T Krusius; E Kolho; R Naukkarinen
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 10.  The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.

Authors:  Kees Fluiter; Olaf R F Mook; Frank Baas
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.